Update on nonpeptide CCK-B receptor antagonists

Drugs of the Future

Volumn 23, Issue 7, 1998, Pages 751-766

  Revel, Laura ^a   Makovec, Francesco ^a  

^a Rotta Research Laboratorium   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 1 (2' METHYLPHENACYL) 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 1 [5 (3 AZABICYCLO[3.2.2]NON 3 YL) 2,3 DIHYDRO 1 METHYL 2 OXO 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 4 [[5 (8 AZASPIRO[4.5]DECAN 8 YL) 4 [(3,5 DICHLOROBENZOYL)AMINO] 5 OXOPENTANOYL]AMINO] 5 (1 NAPHTHYLAMINO) 5 OXOPENTANOIC ACID; 4 AMINOBUTYRIC ACID; ACETAMIDE DERIVATIVE; AMINO ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ OCTAPEPTIDE; EPIRIZOLE; FAMOTIDINE; GASTRIN; GASTRIN 17; GASTRIN RECEPTOR; GLUTAMIC ACID DERIVATIVE; HISTAMINE; INDOMETACIN; METHACHOLINE; OMEPRAZOLE; PENTAGASTRIN; PIPERIDINE DERIVATIVE; PROGLUMIDE; QUINAZOLINONE DERIVATIVE; SPIROGLUMIDE; TETRAGASTRIN; UNINDEXED DRUG;

AMINO ACID COMPOSITION; ANALGESIA; ANALGESIC ACTIVITY; ANXIETY NEUROSIS; DRUG MECHANISM; DRUG STRUCTURE; GASTROINTESTINAL TUMOR; HUMAN; NONHUMAN; PAIN; REVIEW; SCHIZOPHRENIA; STOMACH SECRETION; STOMACH ULCER;

EID: 0031667266     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.07.858363     Document Type: Review

References (124)

1. Mutt, V., Jorpes, J. Structure of porcine cholecystokinin-pancreozymin. Eur J Biochem 1968, 6: 156-62.
2. Frey, P. Cholecystokinin octapeptide (CCK 26-33) nonsulfated octapeptide and tetrapeptide (CCK 30-33) in rat brain: Analysis by high pressure liquid chromatography (HPLC) and radioimmunoassy (RIA). Neurochem Int 1983, 5: 811-5.
3. Eberlein, G.A., Eysselein, V.E., Goebell, H. Cholecystokinin-58 is the major molecular form in man, dog and cat but not in pig, beef and rat intestine. Peptides 1988, 9: 993-8.
4. Crawley, J.E., Corwin, R.L. Biological actions of cholecystokinin. Peptides 1994, 15: 731-55.
5. A receptor antagonists in gastroenterology. Drug News Perspect 1994, 7: 87-95.
6. Liddle, L.A. Cholecystokinin. In: Gut Peptides. Walsh J.H., Dockray, G.J. (Eds.). Raven Press: New York 1994, 175-216.
7. Persson, H., Ericsson, A., Schalling, M., Rehfeld, J.F., Hökfelt, T. Detection of cholecystokinin in spermatogenic cells. Acta Physiol Scand 1988, 134: 565-6.
8. Höckfelt, T., Herrera-Marschitz, M., Seroogy, K. Immunohistochemical studies on cholecystokinin (CCK)-immunoreactive neurons in the rat using sequence specific antisera and with special reference to the caudate nucleus and primary sensory neurons. J Chem Neuroanat 1988, 1: 11-52.
9. Skirboll, L., Höckfelt, T., Rehfeld, J., Cuello, A.C., Dockray, G. Coexistence of substance P- and cholecystokinin-like immunoreactivity in neurons of the mesencephalic periacqueductal central gray. Neurosci Lett 1982, 28: 35-9.
10. Gall, C., Lauterborn, J., Burks, D., Seroogy, K. Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Res 1987, 403: 403-8.
11. Mezey, E., Reisine, T.D., Skirboll, L., Beinfeld, M., Kiss, J.Z. Cholecystokinin in the medial parvocellular subdivision of the paraventricular nucleus. Coexistence with corticotropinreleasing hormone. Ann NY Acad Sci 1985, 448: 152-6.
12. Vanderhaeghen, J.J., Lotstra, F., De May, J., Gilles, C. Immunohistochemical localization of cholecystokinin and gastrin-like peptides in the brain and hypophysis of the rat. Proc Natl Acad Sci USA 1980, 77: 1190-4.
13. Hendry, S.H.C., Jones, E.G., De Felipe, J., Schmechel, D., Brandon, C., Emson, P.C. Neuropeptide-containing neurons of the cerebral cortex are also GABAergic. Proc Natl Acad Sci USA 1984, 81: 6526-30.
14. Kosaka, T., Kosaka, K., Tateishi, K. et al. GABAergic neurons containing CCK-8-like and/or VIP-like immunoreactivities in the rat hippocampus and dentate gyrus. J Comp Neurol 1985, 239: 420-30.
15. McDonald, A.J., Pearson, J.C. Coexistence of GABA and peptide immunoreactivity in non-pyramidal neurons of the baso-lateral amigdala. Neurosci Lett 1989, 100: 53-8.
16. Morino, P., Heffera-Marschitz, M., Castel, M.N. et al. Cholecystokinin in cortico-striatal neurons in the rat: Immunohistochemical studies at the light and electron microscopical level. Eur J Neuroscience 1994, 6: 681-92.
17. Morino, P., Mascagni, M.C., Donald, A., Hökfelt, T. Cholecystokinin corticostriatal pathway in the rat: Evidence for bilateral origin from medial prefrontal cortical areas. Neuroscience 1994, 59: 939-52.
18. Bundgaard, J.R., Vuust, J., Rehfeld, J.F. Tyrosine-O-sulfatation promotes proteolytic processing of progastrin. EMBO J 1995, 14: 3073-9.
19. Walsh, J.H. Gastrin. In: Gut Peptides. Walsh, J.H., Dockray, G.J. (Eds.). Raven Press: New York 1994, 75-121.
20. Rehfeld, J.F., Van Solinge, W.W. The tumor biology of gastrin and cholecystokinin. Adv Cancer Res 1994, 63: 295-347.
21. Watson, S., Abbott, A. TIPS receptor nomenclature supplement. Trends Pharmacol Sci Suppl. 1990, 1-30.
22. Woodruff, G.N., Hughes J. Cholecystokinin antagonists. Ann Rev Pharmacol Toxicol 1991, 31: 469-501.
23. Walsh, J.H. In: Gastrointestinal Hormones in Physiology of the Gastrointestinal Tract, 2nd Ed. Johnos, L.R. (Ed.). Raven Press: New York 1987, 181-259.
24. Enochs, M., Johnson, L. Changes in protein and nucleic acid synthesis in rat gastric mucosa after pentagastrin. Am J Physiol 1977, 223: E223.
25. Modlin, I.M., Tang, L.H. The gastric enterochromaffin-like cell: An enigmatic cellular link. Gastroenterology 1996, 111: 783-810.
26. McGowan, C.C, Cover, T.L., Blaser, M.J. Helicobacter pylori and gastric acid: Biological and therapeutic implications. Gastroenterology 1996, 110: 926-38.
27. Tielemens, Y., Hakanson, R., Willens, G. Hyperplastic manifestations of enterochromaffin-like cells in the stomach of rats with congenital moderate hypergastrinemia. Scand J Gastroenterol 1994, 29: 219-25.
28. Rode, J., Dhillon, A.P., Papadaki, K. et al. Pernicious anaemia and mucosal endocrine cell proliferation of the non-antral stomach. Gut 1986, 27: 789-98.
29. Solcia, E., Capella, C., Fiocca, R., Rindi, G., Rosai, J. Gastric argyrophil carcinoidosis in patients with Zöllinger-Ellison syndrome due to type I multiple endocrine neoplasia. Am J Surg Pathol 1990, 14: 503-13.
30. Rehfeld, J.F. Gastrin and colorectal cancer: A never-ending dispute? Gastroenterology 1995, 108: 1307-10.
31. Creutzfeldt, W., Lamberts, R. Is hypergastrinemia dangerous to man? Scand J Gastroenterol 1991, 26 (Suppl. 180): 179-91.
32. Watson, S.A., Durrant, L.G., Crosbie, J.D., Morris, D.L. The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin. Int J Cancer 1989, 43: 692-6.
33. Upp, J.R. Jr., Sing, P., Townsend, C.M. Jr., Thompson, J.C. Clinical significance of gastrin receptors in human colon cancers. Cancer Res 1989, 49: 488-92.
34. Weinstock, J., Baldwin, G.S. Binding of gastrin-17 to human gastric carcinoma cell lines. Cancer Res 1988, 48: 932-7.
35. Bradwejn, J., De Montigny, C. Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocarnpal neurones. Nature 1984, 312: 363-4.
36. Bradwejn, J., De Montigny, C. Effects of PK8165, a partial benzodiazepine receptor antagonist, on cholecystokinin-induced activation of hippocampal pyramidal neurons: A microiontophoretic study in the rat. Eur J Pharmacol 1985, 112: 415-8.
37. Bouthillier, A., De Montigny, C. Long-term benzodiazepine treatment reduces neuronal responsiveness to cholecystokinin: An electrophysiological study in the rat. Eur J Pharmacol 1988, 151: 135-8.
38. Somogyi, P., Hodgson, A.J., Smith, A.D., Nunzi, M.G., Gorio, A., Wu, J.Y. Different populations of GABAergic neurons in the visual cortex and hippocampus of cat contain somatostatin-or cholecystokinin-immunoreactive material. J Neurosci 1984, 4: 2590-603.
39. B receptors mediate the regulation of exploratory behaviour in the rat. Eur J Pharmacol 1991, 193: 379-81.
40. Abelson, J.L., Nesse, R.M. Cholecystokinin-4 and panic. Arch Gen Psychiatry 1990, 47: 395.
41. De Montigny, C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch Gen Psychiatry 1989, 46: 511-7.
42. Bradwejn, J., Koszycki, D., Payeur, R., Bourin, M., Borthwick, H. Replication of action of cholecystokinin tetrapeptide in panic disorders: Clinical and behavioural findings. Am J Psychiatry 1992, 149: 962-4.
43. Faris, P.L., Komisaruk, B.R., Watkins, L.R., Mayer, D.J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 1983, 219: 310-2.
44. Faris, P.L., McLaughlin, C.L., Baue, C.A., Olney, J.K., Komisaruk, B.R. Morphine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin. Science 1984, 226: 1215-7.
45. Gaudreau, P., Lavigne, G.J., Quirion, R. Cholecystokinin antagonists proglumide, lorglumide and benzotrip, but not L-364,718. interact with brain opioid binding sites. Neuropeptides 1990, 16: 51-5.
46. Wisenfeld-Hallin, Z., Xu, X-J., Hughes, J., Horwell, D.C., Hökfelt, T. PD 134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc Natl Acad Sci USA 1990, 87: 7105-9.
47. Dourish, C.T., O'Neill, M.F., Coughlan, J., Kitchener, S.J., Hawley, D., Iversen, S.D. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Phannacol 1990, 176: 35-44.
48. Losonczy, M.F., Davidson, M., Davis, K.L. The dopamine hypothesis of schizophrenia. In: Psychopharmacology: The Third Generation of Progress. Meltzer, H.Y. (Ed.) Raven Press: New York 1987, 715-26.
49. Hökfelt, T., Rehfeld, J.F., Skirboll, L., Ivemark, B., Goldstein, M., Markey, K. Evidence for coexistence of dopamine and CCK in mesolimbic neurons. Nature 1980, 285: 476-8.
50. Skirboll, L.R., Grace, A.A., Homer, D.W. et al. Peptide-monoamine coexistence: Studies of actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons. Neuroscience 1981, 6: 2111-24.
51. Crawley, J.N., Stivers J.A., Blumstein, K.L., Paul, S.M. Cholecystokinin potentiates dopamine-mediated behaviours: Evidence for modulation specific to a site of coexistence. J Neurosci 1985, 5: 1972-83.
52. Schalling, M., Friberg, K. et al. Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophrenia. Proc Natl Acad Sci USA 1990, 87: 8427-31.
53. Rovati, A.L., Casula, P.L., Dare, G. Anti-secretory action of some new compounds free of anticholinergic actions. Minerva Med 1967, 58: 3651-3.
54. 2-blocking agents. Scand J Gastroenterol 1980, 27: 41-6.
55. Makovec, F., Chistè, R., Bani, M., Revel, L., Setnikar, I., Rovati, L.A. New glutamic and aspartic derivatives with potent CCK-antagonistic activity. Eur J Med Chem 1986, 21: 9-20.
56. Makovec, F., Peris, W., Revel, L., Giovanetti, R., Mennuni, L. Rovati, L.C. Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives. J Med Chem 1992, 35: 28-38.
57. Revel, L., Ferrari, F., Makovec, F., Rovati, L.C., Impicciatore, M. Characterization of antigastrin activity in vivo of CR2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative. Eur J Pharmacol 1992, 216: 217-24.
58. Beltinger, J., Hildebrand, P., Howald, A., D'Amato, M., Beglinger, C. Effect of CR2194, a CCK-B/gastrin-receptor antagonist, on gastrin-stimulated acid secretion in man. Gastroenterology 1994, 106: A50.
59. Makovec, F., Peris, W., Frigerio, S. et al. Structure-antigastrin activity relationships of new spiroglumide amino acid derivatives. J Med Chem 1996, 39: 135-42.
60. B ligands with anxiolytic-like properties. Bioorg Med Chem Lett 1995, 24: 3057-62.
61. Chang, R.S., Lotti, V.J. et al. A potent non-peptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science 1985, 230: 177-9.
62. Evans, B.E., Bock, M.G., Rittle, K.E. et al. Design of potent, orally effective, nonpeptidyl antagonists of the peptide hormone cholecystokinin. Proc Natl Acad Sci USA 1986, 83: 4918-22.
63. Bock, M.G., DiPardo, R.M., Evans, B.E. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. J Med Chem 1989, 32: 13-6.
64. Lee, Y-M., Beinborn, M., McBride, E.W., Lu, M., Kolakowski, L.F. Jr., Kopin, A.S. The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J Biol Chem 1993, 268: 8164-9.
65. Lotti, V.J., Chang, R.S.L. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol 1989, 162: 273-80.
66. Pendley, C.E., Fitzpatrick, L.R., Ewing, R.W., Molino, B.F., Martin, G.E. The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat. J Pharmacol Exp Ther 1993, 265: 1348-54.
67. Murphy, M.G., Sytnich, B., Kovacs, T.O. et al. The gastrin receptor antagonist L-365,260 inhibits stimulated acid secretion in humans. Clin Pharmacol Ther 1993, 54: 533-9.
68. Rataud, J., Darche, F., Piot, O., Stutzmann, J.M., Bohme, G.A., Blanchard, J.C. Anxiolytic effect of CCK-antagonists on plus-maze behaviour in mice. Brain Res 1991, 548: 315-7.
69. Harro, J., Vasar, E. Cholecystokinin-induced anxiety: How is it reflected in studies on exploratory behaviour. Neurosci Biochem Rev 1991, 15: 473-7.
70. B receptor antagonists in ethological and conditioned animal screens for anxiolytics drugs. Psychopharmacology 1995, 121: 109-17.
71. Patel, S., Smith, A.J., Chapman, K.L. et al. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo. Mol Pharmacol 1994, 46: 943-8.
72. Traub, M., Lines, C., Ambrose, J. CCK and anxiety in normal volunteers. Br J Clin Pharmacol 1993, 36: 504P.
73. Bradwejn, J., Koszychi, D., Couetoux du Tertre, A. et al. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 1994, 51: 486-93.
74. Kramer, M.S., Cutler, N., Ballenger, J. et al. A placebo controlled trial of L-365,260, a CCK-B antagonist, in panic disorder. Biol Pscychiatry 1995, 37: 462-6.
75. Watson, S.A., Durrant, L.G., Morris, D.L. Inhibition effect of gastrin receptor antagonist L-365,260 on gastrointestinal tumour cells. Cancer 1991, 68: 1255-60.
76. Pionter, M.K., Hengels, K.J. Differential mode of action of high- and low-affinity CCK/gastrin receptor antagonists in growth inhibition of gastrin-responsive human gastric adenocarcinoma cells in vitro. Anticancer Res 1993, 13: 715-20.
77. Forgue-Lafitte, M.E., Coudray, A.M., Mester, J., Gespach, C., Rosselin, G. Antimitogenic effects of the gastrin-CCK receptors' antagonists L-364718 and L-365260 in human colon cancer cell clone HT29-S-B6: Cell cycle analysis and modulation by serum. Biomed Res 1996, 17: 457-64.
78. Bock, M.G., DiPardo, R.M., Mellin, E.C. et al. Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility. J Med Chem 1994, 37: 722-4.
79. B receptor antagonists by ex vivo binding. Eur J Pharmacol 1994, 237-44.
80. B/gastrin receptor antagonists containing a cationic solubilizing group. J Med Chem 1994, 37: 719-21.
81. Castro, J.L., Ball, R.G., Broughton, H.B. et al. Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-Benzodiazepin-3-yl)-N′-[3-(tetrazol-5-ylamino) phenyl]-ureas. J Med Chem 1996, 39: 842-9.
82. Satoh, M., Kondoh, Y., Okamoto, Y. et al. New 1,4-benzodiazepin-2-one derivatives as gastrin/cholecystokinin-B antagonists. Chem Pharm Bull 1995, 43: 2159-67.
83. Nishida, A., Miyata, K., Tsutsumi, R. et al. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2′-methyl-phenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 1994, 269: 725-31.
84. Nishida, A., Takinami, Y., Yuki, H. et al. YM022, {(R)-1-[2,3-dihydro-1 -(2′-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3- methylphenyl)urea}, a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. J Pharmacol Exp Ther 1994, 270: 1256-61.
85. Yuki, H., Nishida, A., Miyake, A. et al. YM022, a potent and selective gastrin/CCK-B receptor antagonist, inhibits peptone meal-induced gastric acid secretion in Heidenhain pouch dogs. Dig Dis Sci 1997, 42: 707-4.
86. Nishida, A., Kobayashi-Uchida, A., Akuzawa, S. et al. Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression. Am J Physiol 1995, 269: G699-705.
87. Semple, G., Ryder, H., Rooker, D.P. et al. (3R)-N-(tert-Butylcarbonylmethyl)-2,3dihydro-2-oxo-5-(2-pyridyl)-1H-1,4- benzodiazepin-3-yl)-N′-(3-(methylamino)phenyl)urea (YF476): A potent and orally active gastrin/CCK-B antagonist. J Med Chem 1997, 40: 331-41.
88. Takinami, Y., Yuki, H., Nishida, A. et al. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. Aliment Pharmacol Ther 1997, 11: 113-20.
89. Bailey, N., Box, P.C., Carr, R.A.E. et al. Novel 1,5-benzodiazepindione gastrin/CCKB antagonists. Bioorg Med Chem Lett 1997, 7: 281-6.
90. Castro, J.L., Broughton, H.B., Russel, M.G.N. et al. 5-(Piperidin-2-yl)- and 5(homopiperidin-2-yl)-1,4-benzodiazepines: High-affinity, basic ligands for the cholecystokinin-B receptor. J Med Chem 1997, 40: 2491-501.
91. Eden, J.M., Higginbottom, M., Hill, D.R. et al. Rationally designed "dipeptoid" analogues of cholecystokinin (CCK): N-terminal structure-affinity relationships of α-methyltryptophan derivatives. Eur J Med Chem 1993, 28: 37-45.
92. Horwell, D.C., Hughes, J., Hunter, J.C. et al. Rationally designed "dipeptoid" analogues of CCK. α-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. J Med Chem 1991, 34: 404-14.
93. Boden, P.R., Eden, J.M., Higginbottom, M. et al. Rationally designed "dipeptoid" analogues of cholecystokinin (CCK): C-terminal structure-affinity relationships of α-methyltryptophan derivatives. Eur J Med Chem 1993, 28: 47-61.
94. B/gastrin antagonists on stimulated gastric acid secretion in the anaesthetized rat. Br J Pharmacol 1991, 104: 973-7.
95. Hughes, J., Boden, P., Costall, B. et al. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 1990, 87: 6728-32.
96. B receptor antagonist. Br J Pharmacol 1991, 104: 239-45.
97. Costall, B., Domeney, A.M., Hughes, J., Kelly, M.E., Naylor, R.J. Woodruff, G.N. Anxiolytic effects of CCK-B antagonists. Neuropeptides 1991, 19 (Suppl.): 65-73.
98. Dooley, D.L., Klamt, I. Differential profile of CCK-B receptor antagonist CI-988 and diazepam in the four-plate test. Psychopharmacology 1993, 112: 452-4.
99. B receptor ligands in a validated simulation of panic anxiety in rats. Eur Neuropsychopharmacol 1996, 6: 291-8.
100. Bradwejn, J., Koszycki, D., Paradis, M., Reece P., Hinton, J., Sedman, A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatry 1995, 38: 742-6.
101. van Megen, H.J.G.M., Westenberg, H.G.M., den Boer, J.A., Slaap, B., van Es-Radhakishum, F., Pande, A.C. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology 1997, 129: 243-8.
102. Adams, J.B., Pyke, R.E., Costa, J. et al. A double-bind placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol 1995, 15: 428-34.
103. Boden, P.R., Higginbottom, M., Hill, D.R. et al. Cholecystokinin dipeptoid antagonists: Design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists. J Med Chem 1993, 36: 552-65.
104. Augelli-Szafran, C.E., Horwell, D.C., Kneen, C. et al. Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988. Bioorg Med Chem 1996, 4: 1733-45.
105. Araldi, G., Donati, D., Oliosi, B. et al. Synthesis and receptor-binding affinity of dipeptoid cholecystokinin ligands. Eur Med Chem 1996, 31: 215-20.
106. Howbert, J.J., Lobb, K.L., Brown, F.R. et al. A novel series of non-peptide CCK and gastrin antagonists: Medicinal chemistry and electrophysiological demonstration of antagonism. In: Multiple Cholecystokinin Receptors - Progress Towards CNS Therapeutic Targets. Dourish, C.T., Cooper, S.J. (Eds.). Oxford University Press: London 1992, 28-37.
107. B antagonist LY288513. Pharmacol Biochem Behav 1996, 53: 493-502.
108. Rasmussen, K., Helton, D., Berger, J.E., Scearce, E. The CCK-B antagonist LY288513 blocks diazepam withdrawal-induced increases in auditory startle response. Ann NY Acad Sci 1994, 713: 374-6.
109. Yu, M.J., Thrasher, K.J., McCowan, J.R., Mason, N.R., Mendelsohn, L.G. Quinazolinone cholecystokinin-B receptor ligands. J Med Chem 1991, 34: 1505-8.
110. Barret, J.E., Linden, M.C., Holloway, H.C., Yu, M.J., Howbert, J.J. Anxiolytic-like effects of the CCK-B antagonists LY262691. LY262684 and LY247348 on punished responding of squirrel monkeys. Soc Neurosci Abstr 1991, 17: 1063.
111. Rasmussen, K., Czachura, J.F., Stockton, M.E., Howbert, J.J. Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J Pharmacol Exp Ther 1993, 264: 480-8.
112. Rasmussen, K. Therapeutic potential of cholecystokinin-B antagonists. Exp Opin Invest Drugs 1995, 4: 313-22.
113. B/gastrin antagonists. Eur J Pharmacol 1994, 262: 233-45.
114. Pendley, C.E., Fitzpatrick, L.R., Capolino, A.J. et al. RP73870, a gastrin/cholecystokininB receptor antagonist with potent anti-ulcer activity in the rat. J Pharmacol Exp Ther 1995, 273: 1015-22.
115. Kalindjian, S.B., Bodkin, M.J., Buck, I.M. et al. A new class of non-peptidic cholecystokinin-B/gastrin receptor antagonists based on dibenzobyciclo[2.2.2]octane. J Med Chem 1994, 37: 3671-3.
116. Kalindjian, S.B., Buck, I.M., Cushnir, J.R. et al. Improving the affinity and selectivity of a nonpeptide series of cholecystokinin-B/gastrin receptor antagonists based on the dibenzobicyclo[2.2.2]octane skeleton. J Med Chem 1995, 38: 4294-302.
117. Kalindjian, S.B., Buck, I.M., Davies, J.M.R. et al. Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeleton. J Med Chem 1996, 39: 1806-15.
118. Lowe, J.A. III, Hageman, D.L., Drodza, S.E. et al. 5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists. J Med Chem 1994, 37: 3789-811.
119. Lowe, J.A. III, Drodza, S.E., McLean, S. et al. A water soluble benzazepine cholecystokinin-B receptor antagonist. Bioorg Med Chem Lett 1995, 5: 1933-6.
120. B selective receptor ligands: Novel 1,3,5-trisubstituted benzazepin-2-ones. Bioorg Med Chem Lett 1995, 5: 1421-6.
121. B receptor antagonist. Gut 1997, 41 (Suppl. 3): A82.
122. 2 and gastrin receptor antagonists. Bioorg Med Chem Lett 1996, 6: 1427-30.
123. 2 and gastrin receptor antagonist. Chem Pharm Bull 1997, 45: 116-24.
124. Hagishita, S., Murakami, Y., Seno, K. et al. Synthesis and pharmacological properties of ureidomethylcarbamoylphenylketone derivatives. A new potent and subtype-selective nonpeptide CCK-B/gastrin receptor antagonist. S-0509. Bioorg Med Chem 1997, 5: 1695-714.